Welcome to the new Gustave Roussy website
A new website designed to offer you a simpler, clearer, and more intuitive experience. Patients, caregivers, healthcare professionals, and donors: find information, news, and services more easily.
Take part in the 5th edition of the Transatlantic Exchanges
Held on March 27, this fifth edition of the Transatlantic Exchanges will focus on “Transatlantic Innovations in Cancer Drug Research
Published on
Held on March 27, this fifth edition of the Transatlantic Exchanges will focus on “Transatlantic Innovations in Cancer Drug Research”. Registration is now open to attend the event either in person or via videoconference.
The Transatlantic Exchanges are the result of a partnership between Gustave Roussy and the Dana-Farber Cancer Institute, with the support of the Institut Servier. This annual meeting is dedicated to the latest advances in oncology and has been held alternately in Boston and Paris since 2022.
This 5th edition, entitled “Transatlantic Innovations in Cancer Drug Research” will take place on March 27 in Boston. International experts will focus their presentations on epigenetic therapies, microbiome-driven immunity and cellular pathway reprogramming.
These three areas of research illustrate how emerging technologies and innovative approaches are reshaping oncology worldwide through high-level collaborations.
- Epigenic therapies do not aim to alter genes themselves, but rather to regulate their activity, preventing cancer cells from exploiting certain mechanisms to grow.
- Microbiome-driven immunity seeks to understand how the billion of bacteria living in our gut influence the immune system and can enhance the effectiveness of cancer treatments.
- Cellular pathway reprogramming involves blocking or redirecting the internal circuits of cancer cells that enable them to survive, proliferate, or resist treatment.
Professor Laurence Albiges, Head of the Department of Medical Oncology at Gustave Roussy and an international expert in kidney cancer, will co-chair this fifth edition of the Transatlantic Exchanges alongside Professor Toni Choueiri, Director of the Lank Center for Genitourinary Oncology and Medical Director for International Strategic Initiatives at the Dana-Farber Cancer Institute.
Professor Fabrice Barlesi, CEO of Gustave Roussy, and Dr. Laurie Menger, Group Leader of the “Advanced cell therapies” research team at Gustave Roussy, will also take part as moderators.
Registration open
Registration to attend the event, either in person in Boston or remotely, is open to healthcare professionals interested in oncology:
Last news
-
Breast Cancer: Gustave Roussy Ranked No. 1 in France for Breast Surgery and Breast Reconstruction
On the occasion of Breast Cancer Awareness Month, the 2025 data from Visuchir, the national surgical activity monitoring tool of the French Health Insurance system, places Gustave Roussy in first position for both breast surgery and breast reconstruction. Beyond this ranking, these figures highlight that reconstruction is now an integral part of breast cancer treatment. It is considered at every stage of care: from tumor removal surgery, whether lumpectomy or mastectomy, through to the post-cancer period, helping to restore the body and support women in regaining their physical integrity and quality of life.
-
Newsweek Ranking: Gustave Roussy Named Europe’s Leading Cancer Centre and Third Best Worldwide
The 2027 edition of Newsweek’s World's Best Specialized Hospitals ranking once again recognises Gustave Roussy as the leading cancer centre in France and Europe, and the third best worldwide. This distinction highlights the excellence of the Institute’s care and research, as well as the daily commitment of all its professionals.
-
Living with and beyond cancer: the promises and challenges of digital health
In a Viewpoint article published in The Lancet Digital Health, Drs Ines Vaz-Luis and Maria Alice Franzoi, together with Emmanuel Mussault, a patient partner at the PRISM University Hospital Institute, examine the role that digital tools can play in supporting people living with and beyond cancer. Their central message is that these technologies can support more personalised and accessible care, but their value depends primarily on how they are integrated into care pathways, the human support provided, their ability to address individual needs and their evaluation in real-world settings.
-
Gustave Roussy and The Lancet launch an international lecture series on innovations transforming cancer care
The inaugural lecture in the “Lecture Series on Cancer Breakthroughs” will take place on Friday 18 September at 5:00 pm. It will be delivered by Professor Timothy R. Rebbeck, a leading cancer prevention specialist at Harvard University and the Dana-Farber Cancer Institute.
